Thomas Lahlali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thomas Lahlali has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Berzal-Herranz
Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), Av. Conocimiento 17, Armilla, 18016 Granada, Spain
2 shared publications - Beatriz Berzal-Herranz
Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Spain
2 shared publications - Cristina Romero-López
Instituto de Parasitología y Biomedicina López-Neyra (IPBLN-CSIC), Av. Conocimiento 17, Armilla, 18016 Granada, Spain
2 shared publications - Benjamin Ducarouge
INSERM U1052 & CNRS UMR5286, Cancer Research Centre of Lyon, Lyon, France; University of Lyon, Lyon, France; DevWeCan Laboratories of Excellence Network (Labex), Lyon, France
1 shared publication - Cristina Romero-López
Instituto de Parasitología y Biomedicina López-Neyra IPBLN-CSIC, CSIC, Granada, Spain
1 shared publication - Fabien Zoulim
Hepatology Department, Hospices Civils de Lyon, University of Lyon, 69004 Lyon, France
1 shared publication
Latest Publications
- Open Access
- 1 November 2017
- Published by MDPI AG
Multivalent Engineered RNA Molecules that Interfere with Hepatitis C Virus Translation and Replication
The design of novel and efficient compounds fighting against the highly variable RNA viruses, such as hepatitis C virus (HCV), is a major goal. RNA oligonucleotides have gained great interest as specific molecular tools for inhibiting essential viral processes. The combination of different RNA molecules with proven antiviral activity, each with its own activity and specificity, into a single molecule yields the so-called multivalent compounds, which are promising candidates for the development of new therapeutic strategies. These compounds are chimeric entities with enhanced therapeutic properties. In this work, the previously developed chimeric inhibitor RNA HH363-10 was used as archetype for the development of improved anti-HCV inhibitors. HH363-10 consists of a hammerhead ribozyme domain, targeting the essential internal ribosome entry site (IRES) region in the 5’ end of the HCV genome; and an aptamer RNA molecule, directed against the highly conserved IIIf domain of the IRES. As a result of the application of an in vitro selection process to the RNA pool, which results from the partial randomization of the aptamer-domain sequence of the HH363-10 molecule, 10 new multivalent optimized chimeric antiHCV RNA molecules were selected for further analysis. The aptamer RNA domain was evolved to contain two binding sites: the one mapping the IIIf domain, and a newly acquired targeting site, either to the IRES domain IV (which contains the translation start codon) or the essential linker region between the IRES domains I and II. These chimeric molecules efficiently and specifically interfered with HCV IRES-dependent translation in vitro (with IC50 values in the low µM range). They also inhibited both viral translation and replication in cell culture. These findings highlight the feasibility of using in vitro selection strategies for obtaining improved, multivalent RNA molecules with potential clinical applications.
- 1 November 2017
- Published by MDPI AG
Open AccessMultivalent Engineered RNA Molecules that Interfere with Hepatitis C Virus Translation and Replication
The design of novel and efficient compounds fighting against the highly variable RNA viruses, such as hepatitis C virus (HCV), is a major goal. RNA oligonucleotides have gained great interest as specific molecular tools for inhibiting essential viral processes. The combination of different RNA molecules with proven antiviral activity, each with its own activity and specificity, into a single molecule yields the so-called multivalent compounds, which are promising candidates for the development of new therapeutic strategies. These compounds are chimeric entities with enhanced therapeutic properties. In this work, the previously developed chimeric inhibitor RNA HH363-10 was used as archetype for the development of improved anti-HCV inhibitors. HH363-10 consists of a hammerhead ribozyme domain, targeting the essential internal ribosome entry site (IRES) region in the 5’ end of the HCV genome; and an aptamer RNA molecule, directed against the highly conserved IIIf domain of the IRES. As a result of the application of an in vitro selection process to the RNA pool, which results from the partial randomization of the aptamer-domain sequence of the HH363-10 molecule, 10 new multivalent optimized chimeric antiHCV RNA molecules were selected for further analysis. The aptamer RNA domain was evolved to contain two binding sites: the one mapping the IIIf domain, and a newly acquired targeting site, either to the IRES domain IV (which contains the translation start codon) or the essential linker region between the IRES domains I and II. These chimeric molecules efficiently and specifically interfered with HCV IRES-dependent translation in vitro (with IC50 values in the low µM range). They also inhibited both viral translation and replication in cell culture. These findings highlight the feasibility of using in vitro selection strategies for obtaining improved, multivalent RNA molecules with potential clinical applications.
- Open Access
Development of Optimized Inhibitor RNAs Allowing Multisite-Targeting of the HCV Genome
Engineered multivalent drugs are promising candidates for fighting infection by highly variable viruses, such as HCV. The combination into a single molecule of more than one inhibitory domain, each with its own target specificity and even a different mechanism of action, results in drugs with potentially enhanced therapeutic properties. In the present work, the anti-HCV chimeric inhibitor RNA HH363-10, which has a hammerhead catalytic domain and an aptamer RNA domain, was subjected to an in vitro selection strategy to isolate ten different optimised chimeric inhibitor RNAs. The catalytic domain was preserved while the aptamer RNA domain was evolved to contain two binding sites, one mapping to the highly conserved IIIf domain of the HCV genome’s internal ribosome entry site (IRES), and the other either to IRES domain IV (which contains the translation start codon) or the essential linker region between domains I and II. These chimeric molecules efficiently and specifically interfered with HCV IRES-dependent translation in vitro (with IC50 values in the low µM range). They also inhibited both viral translation and replication in cell culture. These findings highlight the feasibility of using in vitro selection strategies for obtaining improved RNA molecules with potential clinical applications.
Open AccessDevelopment of Optimized Inhibitor RNAs Allowing Multisite-Targeting of the HCV Genome
Engineered multivalent drugs are promising candidates for fighting infection by highly variable viruses, such as HCV. The combination into a single molecule of more than one inhibitory domain, each with its own target specificity and even a different mechanism of action, results in drugs with potentially enhanced therapeutic properties. In the present work, the anti-HCV chimeric inhibitor RNA HH363-10, which has a hammerhead catalytic domain and an aptamer RNA domain, was subjected to an in vitro selection strategy to isolate ten different optimised chimeric inhibitor RNAs. The catalytic domain was preserved while the aptamer RNA domain was evolved to contain two binding sites, one mapping to the highly conserved IIIf domain of the HCV genome’s internal ribosome entry site (IRES), and the other either to IRES domain IV (which contains the translation start codon) or the essential linker region between domains I and II. These chimeric molecules efficiently and specifically interfered with HCV IRES-dependent translation in vitro (with IC50 values in the low µM range). They also inhibited both viral translation and replication in cell culture. These findings highlight the feasibility of using in vitro selection strategies for obtaining improved RNA molecules with potential clinical applications.